secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105548
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio appoints William Plovanic to board; expands board to seven members
---------------------------------------------------------------------------

- Board increased from six to seven members; Plovanic appointed as Class I director through 2026 annual meeting.
- Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity; also former CEO/CFO of Obalon Therapeutics.
- Received initial equity grant: option for 17,550 shares (36-month vest) and RSU for 11,925 shares (3-year vest).
- Annual board retainer of $45,000; will receive annual equity awards starting at 2026 meeting (11,700 options + 7,950 RSUs).
- Plovanic is independent under Nasdaq rules; no related party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925105548/0001104659-25-105548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925105548/tm2530000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer